Chemical Name: 1-(8-Bromo-2,3,6,7-tetrahydrobenzodifuran-4-yl)-2-aminoethane hydrochloride
Molecular Formula: C12H14BrNO2.ClH
Formula Weight: 320.612
CAS No.: 178557-21-6
A dihydrodifuran analog of the Schedule I hallucinogen 2C-B, which acts as a partial agonist at the 5-HT2A serotonin receptor; intended for forensic and research purposes
cas: 1337878-62-2 ATI-2341 ATI2341
CBNumber: CB93159454
Chemical Name: ATI-2341
Molecular Formula: C104H178N26O25S2
Formula Weight: 2256.85
CAS No.: 1337878-62-2
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs).
ATI-2341 induces CXCR4- and G protein-dependent signaling, receptor internalization, and chemotaxis in CXCR4-expressing cells. It is the most potent agonist with an EC50 value of 194 ± 16 nM and an intrinsic activity of 81 ± 4%. ATI-2341 is a potent and efficacious mobilizer of bone marrow PMNs(polymorphonuclear neutrophils) and HSPCs(hematopoietic stem and progenitor cells) and could represent a previously undescribed therapeutic approach for the recruitment of HSPCs before ABMT(autologous bone marrow transplantation). ATI-2341 is able to induce chemotaxis of CCRF-CEM cells, inducing the typical bell-shaped curve observed with chemotactic agents
ATI-2341 is a potent and selective allosteric agonist of chemokine CXC-type receptor 4 (CXCR4) that functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 does not promote β-arrestin recruitment. ATI-2341 promotes the mobilization of PMNs and HSPCs in the peripheral circulation of both mice and monkeys.
cas: 3258-02-4 N(4)-hydroxycytidine EIDD-1931
N4-hydroxycytidine and its prodrug EIDD-2801 is being studied for its activity against a number of viral infections including influenza, MERS-CoV, and SARS-CoV-2
N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.1,2 N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage.5 It has shown antiviral activity against Venezuelan equine encephalitis virus,1 and the human coronavirus HCoV-NL63 in vitro.4 N4-hydroxycytodine has been shown to inhibit SARS-CoV-2 as well as other human and bat coronaviruses in mice and human airway epithelial cells.3 It is orally bioavailable in mice and distributes into tissue before becoming the active 5’-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations.2 In non-human primates, N4-hydroxycytidine was poorly orally bioavailable.6 A remdesivir resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.3 The prodrug of N4-hydroxycytidine, EIDD-2801, is also being investigated for its broad spectrum activity against the coronavirus family of viruses.3
N4-Hydroxycytidine (3258-02-4) was originally identified as a mutagen effecting AT to GC base-pair transitions.1 It has also been found to have antiviral properties against a broad range of viruses including hepatitis C2, norovirus3, Ebola virus4, Chikungunya virus5, influenza and respiratory syncytial viruses6, and importantly, coronaviruses.7,8 N4-hydroxycytidine is the active molecule in the antiviral pro-drug clinical candidate EIDD-2801
cas: 19608-29-8 CB-03-01 BREEZULA Hair Loss Cure
What is CB-03-01?
CB-03-01 (cortexolone 17α-propionate, CB0301) 1% cream is a topical androgen receptor inhibitor which has mainly been developed for the treatment of acne vulgaris (1). It is also presently being investigated in a large phase II clinical trial for the topical treatment of male-pattern baldness. CB-03-01 has been found to inhibit the androgen receptor regulated pathway (1). Also known as clascoterone, CB-03-01 is being developed by Cassiopea (a spin-off company from Cosmo Pharmaceuticals) and was initially commercialised as Breezula. Data from 2020 reveal that clascoterone is also being marketed as Winlevi for the management of acne vulgaris. CB-03-01 is thought to compete with DHT for its binding to androgen receptors in both the sebaceous gland and dermal papilla cells within hair follicles. The difference between Winlevi and Breezula is that Breezula is a solution that contains a higher concentration of the drug for the treatment of male-pattern baldness(2). In 2019, Cassiopea announced positive phase II 12-month results for their flagship product Breezula in the management of androgenetic alopecia. The phase II clinical trial recruited in excess of 400 participants in Germany and sought to evaluate the efficacy and safety of 4 different dosing regimens of CB-03-01 compared to vehicle agents in male subjects between the ages of 18 and 55 with mild to moderate male-pattern baldness. All participants were randomised to either apply CB-03-01 or a vehicle agent to balding areas of the scalp daily for 12 months. 5 treatment groups were analysed – 2.5% solution twice-daily, 5.0% solution twice-daily, 7.5% solution twice-daily, 7.5% solution once-daily, and vehicle solution twice-daily.
Researchers used target area hair count (TAHC) and hair growth assessment (HGA) score as the primary end-points of interest. For TAHC, statistically significant changes versus the vehicle agent were observed in all of the active treatment groups, with the most significant improvements observed in the 7.5% twice-daily
cas: 35084-48-1 ACA Nootropic Powder pyrrolidine-2-carboxylic acid
ACA 1-(1 adamantyl carbonyl proline) strengthening the brain promotes intelligence, refreshes, and promotes the development of damaged brain neurons
ACA is smoother than modafinil and blessed with anxiolytic properties. Increased focus is comparable with the afinil family but doesn't seem to leave a crash.
Adamantyl effects are due to an increase in dopamine synthesis, release inhibition uptake and norepinephrine stimulation.
English Name:GSMTX-4
CAS:1209500-46-8 Assay:98%+
Molecular weight:0 Molecular formula: /
Appearance: White powder Remarks: Only for research, not for human
Packing specifications (powder): 1g, 10g, 100g,1kg Storage conditions: -20°C
GsMTx4 is a spider venom peptide that selectively inhibits cationic mechanosensitive channels (MSCs) such as TRPC1 and TRPC6 and Piezo channels. GsMTx4 blocks stretch-activated cation channels in astrocytes, cardiac cells, and smooth and skeletal muscle cells.
GsMTx4 also inhibits TACAN, a mechanosensitive ion channel involved in the pain response. GsMTx4 decreases the leptin-induced AMPK and MLC-2 phosphorylation in breast epithelial cells. GsMTx4 is neuroprotective and inhibits lysophosphatidylcholine-induced astrocyte toxicity in vivo in mice. GsMTx4 suppresses neurogenesis and enhances astrogenesis in human neural stem cells.
GsMTx4 (GsMTx-4, M-theraphotoxin-Gr1a) has been isolated from the venom of the spider Grammostola rosea. This cationic hydrophobic polypeptide blocks selectively the gating of cation selective channels and mechanosensitive ion channels such as TRPC1 or TRPC6, without having any effect on whole-cell voltage-sensitive currents. This toxin acts by perturbing the interface between the channel and the lipid bilayer without necessarily being in physical contact with the channel. GsMTx4 also demonstrated to active TRPA1 channel at 1µM concentration and to inhibit Piezo1 currents.
cas: 1093861-60-9 Anthelmintic Drug Afoxolaner
CBNumber: CB72717660
Chemical Name: afoxolaner
Molecular Formula: C26H17ClF9N3O3
Formula Weight: 625.87
CAS No.: 1093861-60-9
Afoxolaner is the active principle of the veterinary medicinal products (alone), Frontpro (alone) and Spectra (in combination with milbemycin oxime). They are indicated for the treatment and prevention of flea infestations, and the treatment and control of tick infestations in dogs and puppies (8 weeks of age and older, weighing 4 pounds (~1.8 kilograms) of body weight or greater) for one month. These products are administered orally and poisons fleas once they start feeding.
How do I give my dog afoxolaner?
Afoxolaner is given by mouth in the form of a chewable tablet. The tablet should always be given as directed by your veterinarian. It can be given with or without food or water. Be sure the dog consumes the entire dose. If your dog vomits within 2 hours of dosing, give another full dose. Try giving the next dose with food.
afoxolaner contains afoxolaner which is absorbed into the bloodstream after ingestion. When fleas and ticks ingest blood containing afoxolaner, it causes hyperexcitation and death in these parasites.